Microbiotix, Inc. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 51 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Microbiotix, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Microbiotix, Inc. - Product Pipeline Review - 2014', provides an overview of the Microbiotix, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Microbiotix, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Microbiotix, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Microbiotix, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Microbiotix, Inc.'s pipeline products

Reasons to buy

- Evaluate Microbiotix, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Microbiotix, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Microbiotix, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Microbiotix, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Microbiotix, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Microbiotix, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Microbiotix, Inc. Snapshot 6
Microbiotix, Inc. Overview 6
Key Information 6
Key Facts 6
Microbiotix, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Microbiotix, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Microbiotix, Inc. - Pipeline Products Glance 12
Microbiotix, Inc. - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
Microbiotix, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Microbiotix, Inc. - Drug Profiles 15
filociclovir 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
MBX-700 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
MBX-1162 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
MBX-1631 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
MBX-300 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
MBX-500 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
MBX-701 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules to Inhibit 30S RNA for Tuberculosis 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecules to Inhibit T3SS for Pseudomonas Aeruginosa Infections 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MBX-1090 Analogs 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MBX-2319 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MBX-2329 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MBX-2359 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MBX-2546 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule to Inhibit DNA Helicase for Infectious Diseases 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule To Inhibit Hemagglutinin For Influenza A 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules to Block PSAC for Malaria 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Inhibit bNOS for MRSA Infections 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Inhibit BoNT/A LC for Botulism 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Inhibit Cathepsin L for Ebola Virus Infection 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules to Inhibit SAH Hydrolase for Ebola Virus Infection 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit the Fatty Acid Synthesis for Pseudomonas Aeruginosa Infections 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Microbiotix, Inc. - Pipeline Analysis 42
Microbiotix, Inc. - Pipeline Products by Target 42
Microbiotix, Inc. - Pipeline Products by Route of Administration 44
Microbiotix, Inc. - Pipeline Products by Molecule Type 45
Microbiotix, Inc. - Pipeline Products by Mechanism of Action 46
Microbiotix, Inc. - Dormant Projects 48
Microbiotix, Inc. - Locations And Subsidiaries 49
Head Office 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
Microbiotix, Inc., Key Information 6
Microbiotix, Inc., Key Facts 6
Microbiotix, Inc. - Pipeline by Indication, 2014 9
Microbiotix, Inc. - Pipeline by Stage of Development, 2014 10
Microbiotix, Inc. - Monotherapy Products in Pipeline, 2014 11
Microbiotix, Inc. - Phase I, 2014 12
Microbiotix, Inc. - Preclinical, 2014 13
Microbiotix, Inc. - Discovery, 2014 14
Microbiotix, Inc. - Pipeline by Target, 2014 43
Microbiotix, Inc. - Pipeline by Route of Administration, 2014 44
Microbiotix, Inc. - Pipeline by Molecule Type, 2014 45
Microbiotix, Inc. - Pipeline Products by Mechanism of Action, 2014 47
Microbiotix, Inc. - Dormant Developmental Projects,2014 48